Thus, intermediate CD14+CD16+ monocytes isolated from ATB patients at diagnosis have increased expression of genes associated with metabolism, inflammation and MHC-II, and increased capacity to activate T cells upon Mtb antigen exposure, and these characteristics dissipate following 2-3 months of TB therapy. The gene discussed is FCGR3A; the disease is tuberculosis.